Chronic Disease Prevalence Fueling Growth Of AI In Biopharmaceuticals Market: Strategic Insights Driving Artificial Intelligence (AI) In Biopharmaceuticals Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Artificial Intelligence (AI) In Biopharmaceuticals Market Size By 2025?
The biopharmaceutical sector's artificial intelligence (AI) market has experienced significant growth in recent times. This industry is projected to increase from $1.59 billion in 2024 to $2.12 billion in 2025, reflecting a compound annual growth rate (CAGR) of 33.1%. Factors such as improvements in computational capabilities, the surge of biomedical data, the emergence of precision medicine, and regulatory guidance and support have been instrumental in driving growth during the historical period.

How Big Is the Artificial Intelligence (AI) In Biopharmaceuticals Market Size Expected to Grow by 2029?
The market size of artificial intelligence (AI) in biopharmaceuticals is projected to experience a significant surge in the near future. The market is anticipated to augment to $6.67 billion in 2029, with a compound annual growth rate (CAGR) of 33.2%. This projection for the forecast period is underpinned by advancements in fields such as computational biology, multi-modal data integration, the blending of AI and life sciences, supportive regulatory frameworks, and adherence to ethical and fair AI practices. Key trends for this period encompass the incorporation of multi-omics data, AI-driven drug designing and discovery, comprehensible AI and regulatory compliance, technological evolutions, regulatory augmentations, and emerging potentialities.

View the full report here:
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-ai-in-biopharmaceuticals-global-market-report

Which Key Market Drivers Powering Artificial Intelligence (AI) In Biopharmaceuticals Market Expansion and Growth?
The escalating occurrence of long-term illnesses is believed to enhance the expansion of the artificial intelligence (AI) in the biopharmaceuticals market. Chronic illnesses are enduring conditions that generally develop gradually, possibly enduring for a lifetime or several years. These can stem from lifestyle factors, a maturing population, genetic predispositions and environmental determinants. AI, in the sphere of biopharmaceuticals, is being increasingly employed to regulate such illnesses due to its capacity to analyze large quantities of varied data sources, recognize patterns and personalize treatment methods. As an illustration, in November 2023, the Department of Health and Human Services, a governmental body based in the US, reported an 11 percent escalation in newly reported cases of chronic hepatitis B, compared to 2021 in 2022. Consequently, the escalating occurrence of chronic illnesses is responsible for propelling the growth of AI in the biopharmaceuticals market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14251&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Artificial Intelligence (AI) In Biopharmaceuticals Market?
In the biopharmaceutical sector, major corporations specialising in Artificial Intelligence (AI) are making strides in pioneering developments such as AI-empowered solutions for target and lead identification, with the objective to expedite the progression of drug discovery and precision medicine, thereby revolutionizing life sciences organizations. These innovative strategies for drug discovery and precision medicine encompass various methodologies to create new medicinal compounds, and individualize medical treatments to each patient. As an illustration, in May 2023, Google LLC, a firm based in the U.S. providing cloud computing services, debuted two novel AI-driven tools known as the target and lead identification suites, developed to assist scientists in predicting and understanding protein structures which play a pivotal role in the formation of drugs. Furthermore, these suites will aid scientists in processing, storing, examining, and disseminating extensive genomic data, a vital ingredient for precision medicine. Alongside, these tools strive to refine the drug discovery process, lower expenses, and expedite the launch of new treatments in the market. Through efficient data management, precise forecasting of protein structures, and superior genomic analysis capabilities, these tools plan to bring about a transformative change in the drug development procedures, and enhance patient outcomes.

What Are the Emerging Segments in the Artificial Intelligence (AI) In Biopharmaceuticals Market?
The artificial intelligence (AI) in biopharmaceuticals market covered in this report is segmented -

1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Business Process And Supply Chain, Drug Discovery, Medical Imaging And Diagnostics, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes

Subsegments:
1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions
2) By Software: Drug Discovery Platforms, Clinical Trial Management Software, Predictive Analytics Tools, Natural Language Processing Solutions
3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=14251&type=smp

Who Are the Global Leaders in the Artificial Intelligence (AI) In Biopharmaceuticals Market?
Major companies operating in the artificial intelligence (AI) in biopharmaceuticals market are Apple Inc., Google LLC, Microsoft Corporation, Tencent Holdings Limited, Amazon Web Services Inc., International Business Machines Corporation, Exscientia Limited, NVIDIA Corporation, Amgen Inc., DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.

Which are the Top Profitable Regional Markets for the Artificial Intelligence (AI) In Biopharmaceuticals Industry?
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) in biopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14251

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.